Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program

Celmatix, Inc., the leading women’s health biotechnology company focused on ovarian biology, has announced a breakthrough in its novel oral fertility drug program. The program aims to eliminate follicle stimulating hormone (FSH) injections from in vitro fertilization (IVF) and egg freezing protocols, as well as reduce the need for IVF by improving outcomes with ovulation induction and treating m..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 28.
  • textsms

Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis

Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, has announced positive topline results from its first Phase 1 clinical study of FB101. This investigational vaginal microbial immunotherapeutic has shown promising results in treating asymptomatic vaginal dysbiosis. The study was conducted in Europe and evaluated the change in vaginal microbiome after three conse..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 28.
  • textsms